In the presence of pulmonary metastases, locoregional administration of inhaled-IL-2 was reported to yield low toxicity combined with objective response rates of pulmonary disease of 2.5–21% (Lorenz et al, 1996; Merimsky et al, 2004). Here, IL2 is linked to lung disorder.